Sökning: WFRF:(Toivonen Lauri) > The Long-Term Multi...
Fältnamn | Indikatorer | Metadata |
---|---|---|
000 | 05010naa a2200925 4500 | |
001 | oai:DiVA.org:uu-204855 | |
003 | SwePub | |
008 | 130812s2013 | |||||||||||000 ||eng| | |
024 | 7 | a https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-2048552 URI |
024 | 7 | a https://doi.org/10.1161/CIRCULATIONAHA.112.0011392 DOI |
040 | a (SwePub)uu | |
041 | a engb eng | |
042 | 9 SwePub | |
072 | 7 | a ref2 swepub-contenttype |
072 | 7 | a art2 swepub-publicationtype |
100 | 1 | a Connolly, Stuart J.4 aut |
245 | 1 0 | a The Long-Term Multicenter Observational Study of Dabigatran Treatment in Patients With Atrial Fibrillation (RELY-ABLE) Study |
264 | 1 | c 2013 |
338 | a print2 rdacarrier | |
500 | a Clinical Trial Registration URL: Unique identifier: NCT00808067. | |
520 | a Background During follow-up of between 1 and 3 years in the Randomized Evaluation of Long-term Anticoagulation Therapy (RE-LY) trial, 2 doses of dabigatran etexilate were shown to be effective and safe for the prevention of stroke or systemic embolism in patients with atrial fibrillation. There is a need for longer-term follow-up of patients on dabigatran and for further data comparing the 2 dabigatran doses. Methods and Results Patients randomly assigned to dabigatran in RE-LY were eligible for the Long-term Multicenter Extension of Dabigatran Treatment in Patients with Atrial Fibrillation (RELY-ABLE) trial if they had not permanently discontinued study medication at the time of their final RE-LY study visit. Enrolled patients continued to receive the double-blind dabigatran dose received in RE-LY, for up to 28 months of follow up after RE-LY (median follow-up, 2.3 years). There were 5851 patients enrolled, representing 48% of patients originally randomly assigned to receive dabigatran in RE-LY and 86% of RELY-ABLE-eligible patients. Rates of stroke or systemic embolism were 1.46% and 1.60%/y on dabigatran 150 and 110 mg twice daily, respectively (hazard ratio, 0.91; 95% confidence interval, 0.69-1.20). Rates of major hemorrhage were 3.74% and 2.99%/y on dabigatran 150 and 110 mg (hazard ratio, 1.26; 95% confidence interval, 1.04-1.53). Rates of death were 3.02% and 3.10%/y (hazard ratio, 0.97; 95% confidence interval, 0.80-1.19). Rates of hemorrhagic stroke were 0.13% and 0.14%/y. Conclusions During 2.3 years of continued treatment with dabigatran after RE-LY, there was a higher rate of major bleeding with dabigatran 150 mg twice daily in comparison with 110 mg, and similar rates of stroke and death. | |
653 | a atrial fibrillation | |
653 | a dabigatran | |
653 | a hemorrhage | |
653 | a stroke | |
700 | 1 | a Wallentin, Larsu Uppsala universitet,Uppsala kliniska forskningscentrum (UCR),Kardiologi4 aut0 (Swepub:uu)larswall |
700 | 1 | a Ezekowitz, Michael D.4 aut |
700 | 1 | a Eikelboom, John4 aut |
700 | 1 | a Oldgren, Jonasu Uppsala universitet,Uppsala kliniska forskningscentrum (UCR),Kardiologi4 aut0 (Swepub:uu)jonaoldg |
700 | 1 | a Reilly, Paul A.4 aut |
700 | 1 | a Brueckmann, Martina4 aut |
700 | 1 | a Pogue, Janice4 aut |
700 | 1 | a Alings, Marco4 aut |
700 | 1 | a Amerena, John V.4 aut |
700 | 1 | a Avezum, Alvaro4 aut |
700 | 1 | a Baumgartner, Iris4 aut |
700 | 1 | a Budaj, Andrzej J.4 aut |
700 | 1 | a Chen, Jyh-Hong4 aut |
700 | 1 | a Dans, Antonio L.4 aut |
700 | 1 | a Darius, Harald4 aut |
700 | 1 | a Di Pasquale, Giuseppe4 aut |
700 | 1 | a Ferreira, Jorge4 aut |
700 | 1 | a Flaker, Greg C.4 aut |
700 | 1 | a Flather, Marcus D.4 aut |
700 | 1 | a Franzosi, Maria Grazia4 aut |
700 | 1 | a Golitsyn, Sergey P.4 aut |
700 | 1 | a Halon, David A.4 aut |
700 | 1 | a Heidbuchel, Hein4 aut |
700 | 1 | a Hohnloser, Stefan H.4 aut |
700 | 1 | a Huber, Kurt4 aut |
700 | 1 | a Jansky, Petr4 aut |
700 | 1 | a Kamensky, Gabriel4 aut |
700 | 1 | a Keltai, Matyas4 aut |
700 | 1 | a Kim, Sung Soon4 aut |
700 | 1 | a Lau, Chu-Pak4 aut |
700 | 1 | a Le Heuzey, Jean-Yves4 aut |
700 | 1 | a Lewis, Basil S.4 aut |
700 | 1 | a Liu, Lisheng4 aut |
700 | 1 | a Nanas, John4 aut |
700 | 1 | a Omar, Razali4 aut |
700 | 1 | a Pais, Prem4 aut |
700 | 1 | a Pedersen, Knud E.4 aut |
700 | 1 | a Piegas, Leopoldo S.4 aut |
700 | 1 | a Raev, Dimitar4 aut |
700 | 1 | a Smith, Pal J.4 aut |
700 | 1 | a Talajic, Mario4 aut |
700 | 1 | a Tan, Ru San4 aut |
700 | 1 | a Tanomsup, Supachai4 aut |
700 | 1 | a Toivonen, Lauri4 aut |
700 | 1 | a Vinereanu, Dragos4 aut |
700 | 1 | a Xavier, Denis4 aut |
700 | 1 | a Zhu, Jun4 aut |
700 | 1 | a Wang, Susan Q.4 aut |
700 | 1 | a Duffy, Christine O.4 aut |
700 | 1 | a Themeles, Ellison4 aut |
700 | 1 | a Yusuf, Salim4 aut |
710 | 2 | a Uppsala universitetb Uppsala kliniska forskningscentrum (UCR)4 org |
773 | 0 | t Circulationg 128:3, s. 237-243q 128:3<237-243x 0009-7322x 1524-4539 |
856 | 4 8 | u https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-204855 |
856 | 4 8 | u https://doi.org/10.1161/CIRCULATIONAHA.112.001139 |
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
Kopiera och spara länken för att återkomma till aktuell vy